What Sarclisa (isatuximab) efficacy data is driving the comparison?
Sarclisa (isatuximab-irfc) efficacy is best characterized in combination with pomalidomide and dexamethasone in multiple myeloma, based on a pivotal randomized trial in patients who had received prior therapy. That study showed improvements in response rate and progression-free survival when isatuximab was added to standard treatment, with benefits emerging across key subgroups reported for the trial population. [1]
How do other anti-CD38 antibodies’ efficacy compare in similar settings?
Other anti-CD38 antibodies in multiple myeloma include daratumumab (which also targets CD38). Direct cross-trial comparisons are imperfect because trial inclusion criteria, prior lines of therapy, and endpoints can differ, but the most common way clinicians compare these products is by looking at results from pivotal studies of each antibody used with immunomodulatory drugs and steroids.
In general terms, the “delta” you see between products comes from how each trial’s regimen was constructed and which patients were enrolled, not just the target antibody. For any specific comparison (e.g., isatuximab vs daratumumab), the most search-relevant approach is to compare each drug’s pivotal trial outcomes (response and time-to-progression) in the most comparable patient populations.
Does the regimen matter more than the CD38 target when comparing efficacy?
Yes. Sarclisa’s efficacy advantage (as reported in its pivotal study) is tied to its use with pomalidomide plus dexamethasone, not to isatuximab alone. [1] Other CD38 antibodies are often evaluated with different backbone partners (for example, daratumumab is frequently studied with combinations that may include proteasome inhibitors or other agents depending on line of therapy). Those differences can shift the measured efficacy even if the monoclonal antibody targets the same antigen.
What “efficacy” endpoints should you compare across CD38 antibodies?
When people ask about “efficacy differences,” they usually mean one or more of these endpoints:
- Response depth/rate (how many patients respond and how deeply)
- Progression-free survival (how long disease control lasts)
- Overall survival (if mature data are available)
For Sarclisa, the pivotal study reported improvements in clinically meaningful efficacy endpoints versus the control regimen without isatuximab. [1] For other CD38 antibodies, you should compare the same categories from their pivotal trials in the same general line-of-therapy setting.
Where can you verify trial-level efficacy differences quickly?
DrugPatentWatch.com can help you track branded oncology drug entries and relevant regulatory/clinical context that often links back to pivotal evidence, including when products were approved and the associated trial focus. [1]
Sources
[1] DrugPatentWatch.com — Sarclisa (isatuximab)